SCHEMBL6027707

SCHEMBL6027707

CCOC(=O)Cn1cc(C(=O)O)nn1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
LMNA P02545 1/20 0.51
GLA P06280 1/20 0.49
MAPK1 P28482 4/20 0.48
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MAPK14 Q16539 1/20 0.43
PKM P14618 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13827677 0.88 GLA (0.49) ALDH1A1LMNAGLAMAPK1TSHR
SCHEMBL18309087 0.86 GLA (0.48) ALDH1A1LMNAGLAMAPK1TSHR
SCHEMBL15562602 0.84 GLA (0.42) ALDH1A1LMNAGLAMAPK1TSHR
SCHEMBL13819931 0.84 MAPK1 (0.48) ALDH1A1LMNAGLAMAPK1TSHR
SCHEMBL18307624 0.84 GLA (0.46) ALDH1A1LMNAGLAMAPK1TSHR
SCHEMBL908777 0.82 MAPK1 (0.50) ALDH1A1LMNAGLAMAPK1MAPK14
SCHEMBL22576897 0.80 ALDH1A1 (0.38) ALDH1A1LMNAGLAMAPK1TSHR
SCHEMBL28397299 0.80 SRC (0.59) ALDH1A1LMNATSHRMEN1KMT2A
SCHEMBL19010780 0.79 MAPK1 (0.47) ALDH1A1LMNAGLAMAPK1SMN1; SMN2
SCHEMBL14788175 0.79 MAPK1 (0.51) ALDH1A1LMNAGLAMAPK1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US disclosed
EP-1644361-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS Astrazeneca AB (SE) 2006-04-12 EP disclosed
WO-2004113324-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors AURKA, AURKC, AURKB ALDH1A1 2797/4885LMNA 512/4885GLA 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.